Immune to Cancer: The CRI Blog
-
ASCO 2023 Preview — Partnering with Patients: The Cornerstone of Cancer Care and Research
This weekend, the highly anticipated 2023 annual meeting of the American Society of Clinical Oncologists (ASCO) takes… -
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
ASCO 2022 Preview: The Latest Insights from the Front Lines of Cancer Immunotherapy
CRI’s PRINCE Trial featured at ASCO22, along with sessions that highlight the latest clinical advances in checkpoint…
-
ASCO21 Recap: Immunotherapy’s Continued Progress and Addressing Healthcare Disparities
ASCO21 highlighted the latest immunotherapy advances in checkpoint inhibition and cell therapies, and addressed disparities in healthcare.
-
Recapping ASCO20: The Next Horizons in Immunotherapy
The 56th Annual ASCO Meeting highlighted advances in checkpoint immunotherapy, cell-based immunotherapies, and bispecific antibodies.
-
ASCO20 Update: Considerations for Checkpoint Inhibitors Moving Forward
Results unveiled at ASCO20 increased our understanding of checkpoint immunotherapy in a variety of cancers and circumstances.
-
ASCO20 Update: Cellular Immunotherapies, Genomics, and COVID-19
Several promising cellular immunotherapies were discussed at ASCO20, including those for solid cancers; plus updates on the cancer…
-
ASCO20 Preview: Unite & Conquer – Accelerating Progress Together
The ASCO20 Annual Meeting kicks off virtually on Friday, May 31—and advances in immunotherapy will be a…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…